AstraZeneca PLC

AZN

GB0009895292

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

02:00am - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : AstraZeneca should not be overlooked for long

April 03, 2024 at 10:26 am EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

141.1 USD

Average target price

161.4 USD

Spread / Average Target

+14.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+12.75%	219B
ELI LILLY AND COMPANY	+25.61%	660B
NOVO NORDISK A/S	+23.92%	562B
JOHNSON & JOHNSON	-5.24%	358B
MERCK & CO., INC.	+16.49%	322B
ABBVIE INC.	+8.28%	297B
ROCHE HOLDING AG	-9.78%	196B
NOVARTIS AG	+6.89%	199B
PFIZER, INC.	-8.75%	149B
AMGEN INC.	-5.21%	146B

Other Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 04:03:01 2024-04-25 am EDT			5-day change	1st Jan Change
11,916 ^GBX	+4.97%		+9.51%	+12.75%

09:24am	FTSE 100 hits record high on big mining M&A, earnings push	RE
08:58am	Miner Anglo American reviews takeover bid from rival BHP	AN

FTSE 100 hits record high on big mining M&A, earnings push	03:24am	RE
Miner Anglo American reviews takeover bid from rival BHP	02:58am	AN
Miner Anglo American eyes rival BHP takeover	02:44am	AN
AstraZeneca Earnings, Sales Rise, Beat Forecasts	02:37am	DJ
AstraZeneca Reports Growth in Q1 Attributable Profit, Total Revenue	02:30am	MT
Earnings Flash (AZN.L) ASTRAZENECA Posts Q1 EPS $1.40	02:13am	MT
AstraZeneca beats first-quarter revenue, profit estimates	02:06am	RE
AstraZeneca PLC Reports Earnings Results for the First Quarter Ended March 31, 2024	02:00am	CI
Stocks called down ahead of US GDP data	01:50am	AN
Sanofi Q1 profit slips on generic competition, forex effects	01:30am	RE
MORNING BID EUROPE-Gearing up for the tech roller-coaster ride	12:31am	RE
EMEA Morning Briefing : Shares Seen Lower; Earnings, U.S. GDP Data in Focus	12:16am	DJ
No record close for FTSE 100; mixed trade in US	Apr. 24	AN
No record close for FTSE 100; mixed trade in US	Apr. 24	AN
Angle plc to Develop New Cancer Assay in Deal with AstraZeneca	Apr. 24	MT
ASTRAZENECA : Bernstein reiterates its Buy rating	Apr. 24	ZD
Angle shares jump on supplier agreement with with AstraZeneca	Apr. 24	AN
AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook	Apr. 24	AN
Angle PLC Announces New Commercial Agreement with AstraZeneca PLC	Apr. 24	CI
AstraZeneca's Voydeya Approved as Add-on Therapy in Europe for Blood Disorder	Apr. 23	MT
ASTRAZENECA : JP Morgan reaffirms its Buy rating	Apr. 23	ZD
AstraZeneca: Voydeya approved in the EU as a treatment for HPN	Apr. 23	CF
AstraZeneca Obtains EU Approval for Voydeya as Add-on Treatment for Rare Blood Disease	Apr. 23	MT
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
AstraZeneca: presents new data at ECCMID	Apr. 17	CF